DR. PAUL M RIDKER, MD
Osteopathic Medicine at Commonwealth Ave, Boston, MA

2008005, Mar 6, 2008

Mar 12, 2007

11/716996

Uwe Schonbeck - Randolph MA, US
Paul Ridker - Chestnut Hill MA, US
Peter Libby - Boston MA, US

The Brigham and Women's Hospital, Inc. - Boston MA

A61K 31/19, A61K 31/40, A61K 31/435, A61K 31/44, A61P 9/10, G01N 33/00

514277000, 436086000, 514356000, 514415000, 514460000, 514568000

This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.

7964614, Jun 21, 2011

Jun 22, 2005

11/158889

Paul Ridker - Chestnut Hill MA, US
Charles H. Hennekens - Boca Raton FL, US

The Brigham and Women's Hospital, Inc. - Boston MA

A61K 31/47, A61K 31/40, A61K 31/35, A61K 31/21

514311, 514423, 514460, 514510

The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

8101363, Jan 24, 2012

Dec 14, 2001

10/017905

Paul M. Ridker - Chestnut Hill MA, US
JoAnn E. Manson - Beverly MA, US

The Brigham and Women's Hospital, Inc. - Boston MA

G01N 33/53

435 71

The invention involves methods for characterizing an individual's risk profile of developing future diabetes or complications of diabetes by obtaining a level of an inflammatory marker in the individual. Preferred inflammatory markers according to the present invention include C reactive protein and interleukin-6. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future diabetes.

6040147, Mar 21, 2000

Apr 2, 1998

9/054212

Paul Ridker - Chestnut Hill MA
Charles H. Hennekens - South Natick MA

The Brigham and Women's Hospital, Inc. - Boston MA

G01N 3353, G01N 3368

435 724

The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

7030152, Apr 18, 2006

Aug 31, 1999

09/387028

Paul Ridker - Chestnut Hill MA, US
Charles H. Hennekens - Boca Raton FL, US

The Brigham and Women's Hospital, Inc. - Boston MA

A61K 31/40, A61K 31/385, A61K 31/35

514423, 514439, 514460

The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

2004023, Nov 25, 2004

Jan 29, 2004

10/767758

Paul Ridker - Chestnut Hill MA, US
Samuel Goldhaber - Chestnut Hill MA, US
Robert Glynn - Belmont MA, US

A61K031/366

514/457000

A method is provided for inhibiting, preventing or reducing the incidence of venous thromboembolism (VTE) in a patient who previously has undergone standard therapy for VTE, that is, a dose of warfarin of 2 to 3 INR over a 3 to 12 month period, wherein the patient is administered a low dose of warfarin of less than 2 INR and preferably from about 1.4 to less than 2 INR over an extended period of time.

2006011, Jun 1, 2006

Oct 6, 2005

11/244716

Paul Ridker - Chestnut Hill MA, US

The Brigham and Women's Hospital, Inc. - Boston MA

G01N 33/92

436071000

The invention involves, inter alia, the use of markers of systemic inflammation to determine whether or not an individual undergoing treatment with a cardiovascular agent to reduce the risk of a future cardiovascular event will benefit from continued treatment with the cardiovascular agent. Further, this invention describes the use of markers of systemic inflammation to evaluate the efficacy of treatment and to assist physicians in deciding on the course of a treatment in an individual at risk of future cardiovascular events.

2011020, Aug 25, 2011

Apr 19, 2011

13/090116

Paul Ridker - Chestnut Hill MA, US
Daniel Chasman - Cambridge MA, US
Dov Shiffman - Palo Alto CA, US

The Brigham and Women's Hospital, Inc. - Boston MA
Applera Corporation - Norwalk CT

A61K 39/395, C12Q 1/68, A61K 31/616, A61P 9/10, A61P 7/02, A61K 31/4365, A61K 31/727, A61K 31/397, A61K 31/4465

4241331, 435 611, 514165, 514301, 514 56, 51421017, 514331

This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.